Kami J. Maddocks

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

ORCID: 0000-0001-8519-8404

Also affiliated with The Ohio State University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia”.

Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia

Journal of Clinical Oncology(2020)10.1200/jco.20.00491

N/A

3.8DataRank · unranked

105 citations

Ying Huang, Amy S. Ruppert, Lynne V. Abruzzo, Barbara L. Andersen, Farrukh T. Awan +14 more

Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma

Blood(2021)10.1182/blood.2021011894

N/A

1.2DataRank · unranked

35 citations

Melissa M. Berrien-Elliott, Felicia Gomez, Jingqin Luo, Michelle Becker‐Hapak, Amanda F. Cashen +15 more

Illness representations and psychological outcomes in chronic lymphocytic leukaemia

British Journal of Health Psychology(2021)10.1111/bjhp.12562

N/A

0.474DataRank · unranked

10 citations

Thomas R Valentine, John C. Byrd, Jeffrey A. Jones, Kami J. Maddocks, Jennifer A. Woyach +2 more

ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7503

N/A

0.449DataRank · unranked

19 citations

Opeyemi A. Jegede, Peter Martin, Brian G. Till, Samir Parekh, David T. Yang +15 more

Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-center retrospective study

Therapeutic Advances in Hematology(2022)10.1177/20406207221112900

N/A

0.345DataRank · unranked

9 citations

Ying Huang, Emily Dotson, David A. Bond, John Reneau, Narendranath Epperla +7 more

CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7507

N/A

0.312DataRank · unranked

7 citations

Travis Dockter, Amy S. Ruppert, Lale Kostakoglu, Heiko Schöder, Eric D. Hsi +8 more

American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma

Transplantation and Cellular Therapy(2021)10.1016/j.jtct.2021.03.001

N/A

0DataRank · unranked

16 citations

Mehdi Hamadani, Ambuj Kumar, Peter Dreger, Jonathan W. Friedberg, Martin Dreyling +29 more

Transducin β-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma

Haematologica(2020)10.3324/haematol.2020.268235

N/A

0DataRank · unranked

17 citations

Vrajesh Karkhanis, Wing Keung Chan, Frankie Jeney, Alessandro Canella, Xiaoli Zhang +25 more

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

Blood Advances(2022)10.1182/bloodadvances.2022009225

N/A

0DataRank · unranked

11 citations

Jeffrey M. Switchenko, Veronika Bachanová, James N. Gerson, Stefan K. Barta, Max J. Gordon +30 more

A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells

Experimental Hematology and Oncology(2022)10.1186/s40164-022-00293-y

N/A

0DataRank · unranked

10 citations

Pushpa Lata, Youssef Youssef, Ha Tran, Liudmyla Tsyba, Lalit Sehgal +15 more

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

Blood(2023)10.1182/blood.2023021274

N/A

0DataRank · unranked

47 citations

Nicholas Lambert, Paolo F. Caimi, Mwanasha H. Merrill, Priyanka Pullarkat, Richard Godby +19 more

Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell–targeted therapy

JCI Insight(2023)10.1172/jci.insight.163434

N/A

0DataRank · unranked

4 citations

John P. Evans, Madison Sikorski, Karthik B. Chakravarthy, Selah McKenney, Ian Carmody +24 more

Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy

Blood Advances(2021)10.1182/bloodadvances.2021004765

N/A

0DataRank · unranked

41 citations

Jeffrey M. Switchenko, Diego Villa, Kami J. Maddocks, Michael C. Churnetski, Alina S. Gerrie +30 more

Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies

Acta Haematologica(2024)10.1159/000539587

N/A

0DataRank · unranked

1 citations

Catherine C. Coombs, Nirav N. Shah, Wojciech Jurczak, Jennifer A. Woyach, Chan Y. Cheah +16 more

Older patients with mantle cell lymphoma (MCL): Practice patterns and predictors of survival in the rituximab era.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e20064

N/A

0DataRank · unranked

0 citations

Jeffrey M. Switchenko, Subir Goyal, Veronika Bachanová, James N. Gerson, Stefan K. Barta +15 more